Treatment of irritable bowel syndrome

Susan Monica Keating Hadley, Stephen M. Gaarder

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Irritable bowel syndrome affects 10 to 15 percent of the U.S. population to some degree. This condition is defined as abdominal pain and discomfort with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical explanation for these symptoms. Irritable bowel syndrome is more likely to affect women than men and is most common in patients 30 to 50 years of age. Symptoms are improved equally by diets supplemented with fiber or hydrolyzed guar gum, but more patients prefer hydrolyzed guar gum. Antispasmodic agents may be used as needed, but anticholinergic and other side effects limit their use in some patients. Loperamide is an option for treatment of moderately severe diarrhea. Antidepressants have been shown to relieve pain and may be effective in low doses. Trials using alosetron showed a clinically significant, although modest, gain over placebo, but it is indicated only for women with severe diarrhea-predominant symptoms or for those in whom conventional treatment has failed. Tegaserod has an advantage over placebo in constipation-predominant irritable bowel syndrome; it is indicated for up to 12 weeks of treatment in women. However, postmarketing reports of severe diarrhea and ischemic colitis further limit its use. Herbal therapies such as peppermint oil also may be effective in the treatment of irritable bowel syndrome. Therapies should focus on specific gastrointestinal dysfunctions (e.g., constipation, diarrhea, pain), and medications only should be used when nonprescription remedies do not work or when symptoms are severe.

Original languageEnglish (US)
Pages (from-to)2501-2506
Number of pages6
JournalAmerican Family Physician
Volume72
Issue number12
StatePublished - Dec 15 2005
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
guar gum
Diarrhea
Constipation
Placebos
Loperamide
Ischemic Colitis
Phytotherapy
Therapeutics
Pain
Parasympatholytics
Cholinergic Antagonists
Abdominal Pain
Antidepressive Agents
Habits
Diet
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of irritable bowel syndrome. / Hadley, Susan Monica Keating; Gaarder, Stephen M.

In: American Family Physician, Vol. 72, No. 12, 15.12.2005, p. 2501-2506.

Research output: Contribution to journalArticle

Hadley, SMK & Gaarder, SM 2005, 'Treatment of irritable bowel syndrome', American Family Physician, vol. 72, no. 12, pp. 2501-2506.
Hadley, Susan Monica Keating ; Gaarder, Stephen M. / Treatment of irritable bowel syndrome. In: American Family Physician. 2005 ; Vol. 72, No. 12. pp. 2501-2506.
@article{3310379ec4574e3aa219b452393c4fcd,
title = "Treatment of irritable bowel syndrome",
abstract = "Irritable bowel syndrome affects 10 to 15 percent of the U.S. population to some degree. This condition is defined as abdominal pain and discomfort with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical explanation for these symptoms. Irritable bowel syndrome is more likely to affect women than men and is most common in patients 30 to 50 years of age. Symptoms are improved equally by diets supplemented with fiber or hydrolyzed guar gum, but more patients prefer hydrolyzed guar gum. Antispasmodic agents may be used as needed, but anticholinergic and other side effects limit their use in some patients. Loperamide is an option for treatment of moderately severe diarrhea. Antidepressants have been shown to relieve pain and may be effective in low doses. Trials using alosetron showed a clinically significant, although modest, gain over placebo, but it is indicated only for women with severe diarrhea-predominant symptoms or for those in whom conventional treatment has failed. Tegaserod has an advantage over placebo in constipation-predominant irritable bowel syndrome; it is indicated for up to 12 weeks of treatment in women. However, postmarketing reports of severe diarrhea and ischemic colitis further limit its use. Herbal therapies such as peppermint oil also may be effective in the treatment of irritable bowel syndrome. Therapies should focus on specific gastrointestinal dysfunctions (e.g., constipation, diarrhea, pain), and medications only should be used when nonprescription remedies do not work or when symptoms are severe.",
author = "Hadley, {Susan Monica Keating} and Gaarder, {Stephen M.}",
year = "2005",
month = "12",
day = "15",
language = "English (US)",
volume = "72",
pages = "2501--2506",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "12",

}

TY - JOUR

T1 - Treatment of irritable bowel syndrome

AU - Hadley, Susan Monica Keating

AU - Gaarder, Stephen M.

PY - 2005/12/15

Y1 - 2005/12/15

N2 - Irritable bowel syndrome affects 10 to 15 percent of the U.S. population to some degree. This condition is defined as abdominal pain and discomfort with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical explanation for these symptoms. Irritable bowel syndrome is more likely to affect women than men and is most common in patients 30 to 50 years of age. Symptoms are improved equally by diets supplemented with fiber or hydrolyzed guar gum, but more patients prefer hydrolyzed guar gum. Antispasmodic agents may be used as needed, but anticholinergic and other side effects limit their use in some patients. Loperamide is an option for treatment of moderately severe diarrhea. Antidepressants have been shown to relieve pain and may be effective in low doses. Trials using alosetron showed a clinically significant, although modest, gain over placebo, but it is indicated only for women with severe diarrhea-predominant symptoms or for those in whom conventional treatment has failed. Tegaserod has an advantage over placebo in constipation-predominant irritable bowel syndrome; it is indicated for up to 12 weeks of treatment in women. However, postmarketing reports of severe diarrhea and ischemic colitis further limit its use. Herbal therapies such as peppermint oil also may be effective in the treatment of irritable bowel syndrome. Therapies should focus on specific gastrointestinal dysfunctions (e.g., constipation, diarrhea, pain), and medications only should be used when nonprescription remedies do not work or when symptoms are severe.

AB - Irritable bowel syndrome affects 10 to 15 percent of the U.S. population to some degree. This condition is defined as abdominal pain and discomfort with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical explanation for these symptoms. Irritable bowel syndrome is more likely to affect women than men and is most common in patients 30 to 50 years of age. Symptoms are improved equally by diets supplemented with fiber or hydrolyzed guar gum, but more patients prefer hydrolyzed guar gum. Antispasmodic agents may be used as needed, but anticholinergic and other side effects limit their use in some patients. Loperamide is an option for treatment of moderately severe diarrhea. Antidepressants have been shown to relieve pain and may be effective in low doses. Trials using alosetron showed a clinically significant, although modest, gain over placebo, but it is indicated only for women with severe diarrhea-predominant symptoms or for those in whom conventional treatment has failed. Tegaserod has an advantage over placebo in constipation-predominant irritable bowel syndrome; it is indicated for up to 12 weeks of treatment in women. However, postmarketing reports of severe diarrhea and ischemic colitis further limit its use. Herbal therapies such as peppermint oil also may be effective in the treatment of irritable bowel syndrome. Therapies should focus on specific gastrointestinal dysfunctions (e.g., constipation, diarrhea, pain), and medications only should be used when nonprescription remedies do not work or when symptoms are severe.

UR - http://www.scopus.com/inward/record.url?scp=30344445641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344445641&partnerID=8YFLogxK

M3 - Article

C2 - 16370407

AN - SCOPUS:30344445641

VL - 72

SP - 2501

EP - 2506

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 12

ER -